ProBiotic-4 is a probiotic preparation composed of Bifidobacterium lactis,Lactobacillus casei,Bifidobacterium bifidum,and Lactobacillus acidophilus.This study aims to investigate the effects of ProBiotic-4 on the micr...ProBiotic-4 is a probiotic preparation composed of Bifidobacterium lactis,Lactobacillus casei,Bifidobacterium bifidum,and Lactobacillus acidophilus.This study aims to investigate the effects of ProBiotic-4 on the microbiota-gut-brain axis and cognitive deficits,and to explore the underlying molecular mechanism using senescence-accelerated mouse prone 8(SAMP8)mice.ProBiotic-4 was orally administered to 9-month-old SAMP8 mice for 12 weeks.We observed that ProBiotic-4 significantly improved the memory deficits,cerebral neuronal and synaptic injuries,glial activation,and microbiota composition in the feces and brains of aged SAMP8 mice.ProBiotic-4 substantially attenuated aging-related disruption of the intestinal barrier and blood-brain barrier,decreased interleukin-6 and tumor necrosis factor-αat both mRNA and protein levels,reduced plasma and cerebral lipopolysaccharide(LPS)concentration,toll-like receptor 4(TLR4)expression,and nuclear factor-κB(NF-κB)nuclear translocation in the brain.In addition,not only did ProBiotic-4 significantly decreased the levels ofγ-H2 AX,8-hydroxydesoxyguanosine,and retinoic-acid-inducible gene-I(RIG-I),it also abrogated RIG-I multimerization in the brain.These findings suggest that targeting gut microbiota with probiotics may have a therapeutic potential for the deficits of the microbiota-gut-brain axis and cognitive function in aging,and that its mechanism is associated with inhibition of both TLR4-and RIG-I-mediated NF-κB signaling pathway and inflammatory responses.展开更多
Psychological stress is an important factor for the development of irritable bowel syndrome(IBS). More and more clinical and experimental evidence showed that IBS is a combination of irritable bowel and irritable brai...Psychological stress is an important factor for the development of irritable bowel syndrome(IBS). More and more clinical and experimental evidence showed that IBS is a combination of irritable bowel and irritable brain. In the present review we discuss the potential role of psychological stress in the pathogenesis of IBS and provide comprehensive approaches in clinical treatment. Evidence from clinical and experimental studies showed that psychological stresses have marked impact on intestinal sensitivity, motility, secretion and permeability, and the underlying mechanism has a close correlation with mucosal immune activation, alterations in central nervous system, peripheral neurons and gastrointestinal microbiota. Stress-induced alterations in neuro-endocrine-immune pathways acts on the gut-brain axis and microbiota-gut-brain axis, and cause symptom flare-ups or exaggeration in IBS. IBS is a stresssensitive disorder, therefore, the treatment of IBS should focus on managing stress and stress-induced responses. Now, non-pharmacological approaches and pharmacological strategies that target on stress-related alterations, such as antidepressants, antipsychotics, miscellaneous agents, 5-HT synthesis inhibitors, selective 5-HT reuptake inhibitors, and specific 5-HT receptor antagonists or agonists have shown a critical role in IBS management. A integrative approach for IBS management is a necessary.展开更多
The gut-brain axis is a bidirectional information interaction system between the central nervous system(CNS) and the gastrointestinal tract, in which gut microbiota plays a key role. The gut microbiota forms a complex...The gut-brain axis is a bidirectional information interaction system between the central nervous system(CNS) and the gastrointestinal tract, in which gut microbiota plays a key role. The gut microbiota forms a complex network with the enteric nervous system, the autonomic nervous system, and the neuroendocrine and neuroimmunity of the CNS, which is called the microbiota-gut-brain axis. Due to the close anatomical and functional interaction of the gut-liver axis, the microbiota-gut-liver-brain axis has attracted increased attention in recent years. The microbiota-gut-liver-brain axis mediates the occurrence and development of many diseases, and it offers a direction for the research of disease treatment. In this review, we mainly discuss the role of the gut microbiota in the irritable bowel syndrome, inflammatory bowel disease, functional dyspepsia, non-alcoholic fatty liver disease, alcoholic liver disease, cirrhosis and hepatic encephalopathy via the gut-liver-brain axis, and the focus is to clarify the potential mechanisms and treatment of digestive diseases based on the further understanding of the microbiota-gut-liver-brain axis.展开更多
Parkinson’s disease(PD)is the second most common neurodegenerative disease,but none of the current treatments for PD can halt the progress of the disease due to the limited understanding of the pathogenesis.In PD dev...Parkinson’s disease(PD)is the second most common neurodegenerative disease,but none of the current treatments for PD can halt the progress of the disease due to the limited understanding of the pathogenesis.In PD development,the communication between the brain and the gastrointestinal system influenced by gut microbiota is known as microbiota-gut-brain axis.However,the explicit mechanisms of microbiota dysbiosis in PD development have not been well elucidated yet.FLZ,a novel squamosamide derivative,has been proved to be effective in many PD models and is undergoing the phase I clinical trial to treat PD in China.Moreover,our previous pharmacokinetic study revealed that gut microbiota could regulate the absorption of FLZ in vivo.The aims of our study were to assess the protective effects of FLZ treatment on PD and to further explore the underlying microbiota-related mechanisms of PD by using FLZ as a tool.In the current study,chronic oral administration of rotenone was utilized to induce a mouse model to mimic the pathological process of PD.Here we revealed that FLZ treatment alleviated gastrointestinal dysfunctions,motor symptoms,and dopaminergic neuron death in rotenone-challenged mice.16 S rRNA sequencing found that PD-related microbiota alterations induced by rotenone were reversed by FLZ treatment.Remarkably,FLZ administration attenuated intestinal inflammation and gut barrier destruction,which subsequently inhibited systemic inflammation.Eventually,FLZ treatment restored blood-brain barrier structure and suppressed neuroinflammation by inhibiting the activation of astrocytes and microglia in the substantia nigra(SN).Further mechanistic research demonstrated that FLZ treatment suppressed the TLR4/MyD88/NF-κB pathway both in the SN and colon.Collectively,FLZ treatment ameliorates microbiota dysbiosis to protect the PD model via inhibiting TLR4 pathway,which contributes to one of the underlying mechanisms beneath its neuroprotective effects.Our research also supports the importance of microbiota-gut-brain ax展开更多
Fecal microbiota transplantation(FMT)has been used as a core therapy for treating dysbiosis-related diseases by remodeling gut microbiota.The methodology and technology for improving FMT are stepping forward,mainly in...Fecal microbiota transplantation(FMT)has been used as a core therapy for treating dysbiosis-related diseases by remodeling gut microbiota.The methodology and technology for improving FMT are stepping forward,mainly including washed microbiota transplantation(WMT),colonic transendoscopic enteral tubing(TET)for microbiota delivery,and purified Firmicutes spores from fecal matter.To improve the understanding of the clinical applications of FMT,we performed a systematic literature review on FMT published from 2011 to 2021.Here,we provided an overview of the reported clinical benefits of FMT,the methodology of processing FMT,the strategy of using FMT,and the regulations on FMT from a global perspective.A total of 782 studies were included for the final analysis.The present review profiled the effectiveness from all clinical FMT uses in 85 specific diseases as eight categories,including infections,gut diseases,microbiotagut-liver axis,microbiotagut-brain axis,metabolic diseases,oncology,hematological diseases,and other diseases.Although many further controlled trials will be needed,the dramatic increasing reports have shown the promising future of FMT for dysbiosis-related diseases in the gut or beyond the gut.展开更多
基金supported by the National Natural Science Foundation of China(81473219 and 81973307)partly by 111 Project of the National Ministry of Education(B18035,China).
文摘ProBiotic-4 is a probiotic preparation composed of Bifidobacterium lactis,Lactobacillus casei,Bifidobacterium bifidum,and Lactobacillus acidophilus.This study aims to investigate the effects of ProBiotic-4 on the microbiota-gut-brain axis and cognitive deficits,and to explore the underlying molecular mechanism using senescence-accelerated mouse prone 8(SAMP8)mice.ProBiotic-4 was orally administered to 9-month-old SAMP8 mice for 12 weeks.We observed that ProBiotic-4 significantly improved the memory deficits,cerebral neuronal and synaptic injuries,glial activation,and microbiota composition in the feces and brains of aged SAMP8 mice.ProBiotic-4 substantially attenuated aging-related disruption of the intestinal barrier and blood-brain barrier,decreased interleukin-6 and tumor necrosis factor-αat both mRNA and protein levels,reduced plasma and cerebral lipopolysaccharide(LPS)concentration,toll-like receptor 4(TLR4)expression,and nuclear factor-κB(NF-κB)nuclear translocation in the brain.In addition,not only did ProBiotic-4 significantly decreased the levels ofγ-H2 AX,8-hydroxydesoxyguanosine,and retinoic-acid-inducible gene-I(RIG-I),it also abrogated RIG-I multimerization in the brain.These findings suggest that targeting gut microbiota with probiotics may have a therapeutic potential for the deficits of the microbiota-gut-brain axis and cognitive function in aging,and that its mechanism is associated with inhibition of both TLR4-and RIG-I-mediated NF-κB signaling pathway and inflammatory responses.
文摘Psychological stress is an important factor for the development of irritable bowel syndrome(IBS). More and more clinical and experimental evidence showed that IBS is a combination of irritable bowel and irritable brain. In the present review we discuss the potential role of psychological stress in the pathogenesis of IBS and provide comprehensive approaches in clinical treatment. Evidence from clinical and experimental studies showed that psychological stresses have marked impact on intestinal sensitivity, motility, secretion and permeability, and the underlying mechanism has a close correlation with mucosal immune activation, alterations in central nervous system, peripheral neurons and gastrointestinal microbiota. Stress-induced alterations in neuro-endocrine-immune pathways acts on the gut-brain axis and microbiota-gut-brain axis, and cause symptom flare-ups or exaggeration in IBS. IBS is a stresssensitive disorder, therefore, the treatment of IBS should focus on managing stress and stress-induced responses. Now, non-pharmacological approaches and pharmacological strategies that target on stress-related alterations, such as antidepressants, antipsychotics, miscellaneous agents, 5-HT synthesis inhibitors, selective 5-HT reuptake inhibitors, and specific 5-HT receptor antagonists or agonists have shown a critical role in IBS management. A integrative approach for IBS management is a necessary.
基金Supported by the National Natural Science Foundation of China,No. 81970541,No. 31960151,No. 81660099 and No. 81660412。
文摘The gut-brain axis is a bidirectional information interaction system between the central nervous system(CNS) and the gastrointestinal tract, in which gut microbiota plays a key role. The gut microbiota forms a complex network with the enteric nervous system, the autonomic nervous system, and the neuroendocrine and neuroimmunity of the CNS, which is called the microbiota-gut-brain axis. Due to the close anatomical and functional interaction of the gut-liver axis, the microbiota-gut-liver-brain axis has attracted increased attention in recent years. The microbiota-gut-liver-brain axis mediates the occurrence and development of many diseases, and it offers a direction for the research of disease treatment. In this review, we mainly discuss the role of the gut microbiota in the irritable bowel syndrome, inflammatory bowel disease, functional dyspepsia, non-alcoholic fatty liver disease, alcoholic liver disease, cirrhosis and hepatic encephalopathy via the gut-liver-brain axis, and the focus is to clarify the potential mechanisms and treatment of digestive diseases based on the further understanding of the microbiota-gut-liver-brain axis.
基金supported by grants from National Sciences Foundation of China(81773718,81630097,and 81773589)The National Key Research and Development Program of China(Grant No.SQ2018YFA090025-04)+3 种基金CAMS Innovation Fund for Medical Sciences(No.2016-I2M-3e011,China)The Drug Innovation Major Project(2018ZX09711001-003-020,2018ZX09711001-003-005,and 2018ZX09711001-008-005,China)CAMS The Fundamental Research Funds for the Central Universities(2018RC350002,China)CAMS&PUMC Innovation Fund for Graduate(No.2019-1007-23,China)
文摘Parkinson’s disease(PD)is the second most common neurodegenerative disease,but none of the current treatments for PD can halt the progress of the disease due to the limited understanding of the pathogenesis.In PD development,the communication between the brain and the gastrointestinal system influenced by gut microbiota is known as microbiota-gut-brain axis.However,the explicit mechanisms of microbiota dysbiosis in PD development have not been well elucidated yet.FLZ,a novel squamosamide derivative,has been proved to be effective in many PD models and is undergoing the phase I clinical trial to treat PD in China.Moreover,our previous pharmacokinetic study revealed that gut microbiota could regulate the absorption of FLZ in vivo.The aims of our study were to assess the protective effects of FLZ treatment on PD and to further explore the underlying microbiota-related mechanisms of PD by using FLZ as a tool.In the current study,chronic oral administration of rotenone was utilized to induce a mouse model to mimic the pathological process of PD.Here we revealed that FLZ treatment alleviated gastrointestinal dysfunctions,motor symptoms,and dopaminergic neuron death in rotenone-challenged mice.16 S rRNA sequencing found that PD-related microbiota alterations induced by rotenone were reversed by FLZ treatment.Remarkably,FLZ administration attenuated intestinal inflammation and gut barrier destruction,which subsequently inhibited systemic inflammation.Eventually,FLZ treatment restored blood-brain barrier structure and suppressed neuroinflammation by inhibiting the activation of astrocytes and microglia in the substantia nigra(SN).Further mechanistic research demonstrated that FLZ treatment suppressed the TLR4/MyD88/NF-κB pathway both in the SN and colon.Collectively,FLZ treatment ameliorates microbiota dysbiosis to protect the PD model via inhibiting TLR4 pathway,which contributes to one of the underlying mechanisms beneath its neuroprotective effects.Our research also supports the importance of microbiota-gut-brain ax
基金supported by a grant from the National Natural Science Foundation of China(No. 81873548)the Nanjing Medical University Fan Daiming Research Funds for Holistic Integrative Medicine.
文摘Fecal microbiota transplantation(FMT)has been used as a core therapy for treating dysbiosis-related diseases by remodeling gut microbiota.The methodology and technology for improving FMT are stepping forward,mainly including washed microbiota transplantation(WMT),colonic transendoscopic enteral tubing(TET)for microbiota delivery,and purified Firmicutes spores from fecal matter.To improve the understanding of the clinical applications of FMT,we performed a systematic literature review on FMT published from 2011 to 2021.Here,we provided an overview of the reported clinical benefits of FMT,the methodology of processing FMT,the strategy of using FMT,and the regulations on FMT from a global perspective.A total of 782 studies were included for the final analysis.The present review profiled the effectiveness from all clinical FMT uses in 85 specific diseases as eight categories,including infections,gut diseases,microbiotagut-liver axis,microbiotagut-brain axis,metabolic diseases,oncology,hematological diseases,and other diseases.Although many further controlled trials will be needed,the dramatic increasing reports have shown the promising future of FMT for dysbiosis-related diseases in the gut or beyond the gut.
